Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-041194
Filing Date
2025-03-18
Accepted
2025-03-18 16:14:04
Documents
92
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K trvi-20241231.htm   iXBRL 10-K 3094098
2 EX-10.7 trvi-ex10_7.htm EX-10.7 7161
3 EX-19.1 trvi-ex19_1.htm EX-19.1 106368
4 EX-23.1 trvi-ex23_1.htm EX-23.1 6661
5 EX-31.1 trvi-ex31_1.htm EX-31.1 17454
6 EX-31.2 trvi-ex31_2.htm EX-31.2 17698
7 EX-32.1 trvi-ex32_1.htm EX-32.1 11246
8 EX-32.2 trvi-ex32_2.htm EX-32.2 10918
9 GRAPHIC img24633819_0.jpg GRAPHIC 205643
  Complete submission text file 0000950170-25-041194.txt   12906843

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20241231.xsd EX-101.SCH 1655869
95 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20241231_htm.xml XML 2171844
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38886 | Film No.: 25748469
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)